NDAINJECTIONINJECTABLE
Approved
May 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug Shortage Active
RIFADIN is currently in shortage. Reason: Available. This may impact manufacturing, supply chain, and quality hiring at the manufacturer.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RIFADIN (rifampin) is a rifamycin-class small-molecule antibiotic that inhibits bacterial DNA-dependent RNA polymerase, making it bactericidal against Mycobacterium tuberculosis and other mycobacteria. It is indicated for tuberculosis, leprosy, mycobacterium avium complex infection, and as adjunctive therapy in HIV infection. The drug is rapidly absorbed orally, widely distributed including to cerebrospinal fluid, and undergoes hepatic metabolism with enterohepatic circulation.
LOE Approaching
As loss of exclusivity approaches, brand team focus will shift from growth to lifecycle management and generic transition strategy, with likely team restructuring.
Mechanism of Action
Pharmacologic Class:
Rifamycin Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Drug-Drug Interaction Study of MDR-001 With Rifampin and Itraconazole in Healthy Adult Participants
Started May 2026
28 enrolled
Healthy Volunteers (HV)
Therapeutic Drug Monitoring for Linezolid in the Treatment of Rifampin-resistant Tuberculosis
Started Apr 2026
280 enrolled
Rifampin-resistant TuberculosisDrug-resistant Tuberculosis
A Study Evaluating the Effects of Itraconazole or Rifampin on the Pharmacokinetic Characteristics of Rocbrutinib Tablet
Started Mar 2026
28 enrolled
Clinical Pharmacology
A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants
Started Dec 2025
42 enrolled
Healthy Volunteers
Dolutegravir/Lamivudine Dual Therapy for ART-naïve People With HIV and TB Receiving Rifampin-based TB Treatment
Started Sep 2025
150 enrolled
TuberculosisHIV
Worked on RIFADIN at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.